Strategic Partnerships Quidel has a history of collaborating with industry leaders and institutions (Beckman Coulter, Global Lyme Alliance, Relo Metrics partnerships) which indicates openness to co-development, distribution deals, and alliance-based go-to-market strategies that could be leveraged for new diagnostic platforms, assays, or regional expansion.

MDx Platform The launch of Savanna, Quidel’s long-awaited MDx platform, signals a strategic push into molecular diagnostics and point-of-care solutions. This creates opportunities to offer complementary assays, data analytics, cloud-enabled workflow integration, and managed services to healthcare providers.

Expansion Potential Acquisition of Mesa Biotech and ongoing international demand for rapid infectious disease diagnostics suggest room to upsell or cross-sell additional tests, cartridge-based assays, or bundled preventive care solutions to existing customers and new geographies.

Regulatory & Sustainability Active regulatory and governance work, including a Conflict Minerals Report, indicates a mature compliance program. This can be a selling point when engaging with healthcare organizations prioritizing supplier ESG criteria, risk management, and transparent supply chains.

Financial Signals Current revenue range indicates mid-market focus with room to scale. Sales conversations can emphasize cost-per-test benefits, total cost of ownership for point-of-care solutions, and ROI through faster diagnoses and improved patient outcomes.